Taurine attenuates fanconi syndrome induced by ifosfamide without compromising its antitumor activity

Oncology Research

Volumn 10, Issue 7, 1998, Pages 355-360

  Badary, Osama A ^a,b  

^a African Union Organization St Abbassia   (Egypt)

^b Bioanalysis Research Group   (Egypt)

Author keywords

Antitumor activity; Fanconi syndrome; Ifosfamide; Nephrotoxicity; Taurine

Indexed keywords

IFOSFAMIDE; TAURINE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; EHRLICH ASCITES TUMOR; FANCONI RENOTUBULAR SYNDROME; FEMALE; MALE; MOUSE; PATHOPHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; CARCINOMA, EHRLICH TUMOR; FANCONI SYNDROME; FEMALE; IFOSFAMIDE; MALE; MICE; NEOPLASM TRANSPLANTATION; RATS; RATS, WISTAR; TAURINE;

EID: 0032248875     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Brade, W. P.; Herdrich, K.; Kachel-Fischer, U.; Araujo, C. E. Dosing and side effects of ifosfamide plus mesna. J. Cancer Res. Clin. Oncol. 117:S164-S186; 1991.
2. Brade, W. P.; Seeber, S.; Herdrich, K. Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother. Pharmacol. 18:S1-S9; 1986.
3. Skinner, R.; Sharkey, I. M.; Pearson, A. D.; Craft, A. W. Ifosfamide, mesna and nephrotoxicty in children. J. Clin. Oncol. 11:173-190; 1993.
4. Rosen, G.; Forscher F.; Lowenbraum, S.; Eliber, F.; Eckardt, J.; Holmes, C.; Fu, Y. S. Uniform response of metastases to high dose ifosfamide. Cancer 73:2505-2511; 1994.
5. Burk, C. D.; Restaino, I.; Kaplan, B. S.; Medows, A. T. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J. Pediatr. 117:331-335; 1990.
6. Pratt, C. B.; Meyer, W. H.; Jenkins, T. J.; Avery, L.; McKay, C. P.; Wyatt, R. J.; Hancock, M. L. Ifosfamide, Fanconi-syndrome, rickets. J. Clin. Oncol. 9:1495-1499; 1991.
7. Berns, J. S.; Haghighat, A.; Staddon, A. Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Cancer 76:497-500; 1995.
8. English, M. W.; Skinner, R.; Pearson, A. D.; Price, L.; Wyllie, R.; Craft, A. W. The influence of ifosfamide scheduling on acute nephrotoxicity in children. Br. J. Cancer 75:1356-1359; 1997.
9. Tokuc, G.; Yalciner, A.; Kebudi, R.; Dogan, S.; Gorgun, O.; Ayan, I. Renal dysfunctions secondary to ifosfamide treatment in children. J. Exp. Clin. Cancer Res. 16:227-230; 1997.
10. Elias, A. D.; Eder, J. P.; Shea, T.; Begg, C. B.; Frei, E.; Antman, K. H. High dose ifosfamide with mesna uroprotection: A phase I study. J. Clin. Oncol. 8:170-178; 1990.
11. Rossi, R.; Godde, A; Kleinebrand, A.; Riepenhausen, M.; Boos, J.; Ritter, J.; Jurgens, H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients. J. Clin. Oncol. 12:159-165; 1994.
12. Foreman, J. W.; Bowring, M. A.; Lee, J. Effect of cystine dimethylester on renal solute handling and isolated renal tubule transport in the rat. A new model of the Fanconi syndrome. Metabolism 36:1185-1191; 1987.
13. Foreman, J. W.; Benson, L. L.; Mellons, M.; Avener, E. D.; Sweeney, W.; Nissim, I. Metabolic studies of rat tubule cells loaded with cystine: The cystine dimethylester (CDE) model of cystinosis. J. Am. Soc. Nephrol. 6:269-272; 1995.
14. Nissim, I.; Weinberg, J. M. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int. 49:684-695; 1996.
15. Nakanashi, T.; Takamitsu, Y.; Sugita, M. Role of taurine in the kidney: Osmoregulatory taurine accumulation in renal medulla. In: Huxtable, R. J.; Micholk, D., eds. Taurine in health and disease. New York: Plenum Press; 1994:139-148.
16. Huxtable, R. J. Physiological actions of taurine. Physiol. Rev. 72: 101-103; 1992.
17. Sturman, J. A. Taurine in development. Physiol. Rev. 73:119-147; 1993.
18. Schaffer, S. W.; Azuma, J.; Madura, J. D. Mechanisms underlying taurine-mediated alterations in membrane function. Amino Acids 8:231-246; 1995.
19. Halliwell, B.; Gutteridge, J. M. C. The antioxidants of human extracellular fluid. Arch. Biochem. Biophys. 280:1-8; 1990.
20. Trachtman, H.; DelPizzo, R.; Futterweit, S.; Levine, D.; Rao, P. S.; Valderroma, E.; Sturman, J. A. Taurine attenuates renal disease in chronic puromycin aminonucleoside nephropathy. Am. J. Physiol. 262:F117-F123; 1992.
21. Okada, S.; Hamazaki, S.; Ebina, Y.; Li, J. L.; Modorkawa, O. Nephrotoxicity and its prevention in ferric nitrilotriacetate-promoted lipid peroxidation. Biochim. Biophys. Acta 922:28-33; 1987.
22. Trachtman, H.; Futterweit, S.; Maesaka, J.; Ma, C.; Valderrama,
23. E.; Fuchs, A.; Tarectecan, A. A.; Rao, P. S.; Sturman, J. A.; Boles, T. H.; Fu, M.; Baynes, A. J. Taurine ameliorates chronic streptozotocin-induced diabetic nephropathy in rats. Am. J. Physiol. 269: F429-F438; 1995.
24. Venkatesan, N.; Venkatesan, P.; Karthikeyan, J.; Arumugam, V. Protection by taurine against adriamycin-induced proteinuria and hyperlipidemia in rats. Proc. Soc. Exp. Biol. 215:158-164; 1997.
25. Goren, M. P.; Weight, F. K.; Horowitz, M. E.; Pratt, C. B. Ifosfamide induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat. Rep. 71:331-335; 1990.
26. Patton, C. J.; Crouch, S. R. Spectrophotometric and kinetics investigations of the Berthelot reaction for the determination of ammonia. Anal. Chem. 49:464-469; 1977.
27. Bartles, H.; Bohmer, M.; Heieri, C. Serum Kreatinin bestimmung ohno enteiweissen. Clin. Chim. Acta 37:193-197; 1972.
28. Trinder, P. Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J. Clin. Pathol. 22:246; 1969.
29. Varley, H. Methods for albumin using dye-binding. In: Practical clinical biochemistry. Delhi: CBS Publishers and Distributors; 1988:243.
30. Noll, F. L-(+)-Lactate. Determination with LDH, GPT and NAD. In: Bergmeyer, H. U., ed. Methods for enzymatic analysis, 2nd ed. New York/London: Verlag Chemie Weinheim and Academic Press, Inc.; 1974:1475.
31. Czok, R.; Lamprecht, W. Pyruvate, phosphoenol-pyruvate and D-glycerale-2-phosphate. In: Bergmeyer, H. U., ed. Methods for enzymatic analysis, 2nd ed. New York/London: Verlag Chemie Weinheim and Academic Press, Inc.; 1974:1446.
32. Uchiyama, M.; Mihara, M. Determination of malonadehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86: 271-278; 1978.
33. Ellman, G. L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77; 1959.
34. Habig, W. H.; Pabst, M. J.; Jakoby, W. B. Glutathione S-transfetases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249:7130-7139; 1974.
35. Benson, A. M.; Hunkeler, M. J.; Talalay, P. Increase of NAD(P)H: Quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. USA 77:5216-5220; 1980.
36. Kokko, J. P.; Tannen, R. L., eds. Fluids, electrolytes. Philadelphia: W. B. Saunders Co.; 1986.
37. Geran, R. I.; Greenberg, N. H.; MacDonald, M.; Schumacher, A. M.; Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3:1-103; 1972.
38. Bokemeyer, C.; Schmoll, H. J.; Ludwig, E.; Harstrick, A.; Dunn, T.; Casper, J. The anti-tumor activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by uroprotector mesna. Br. J. Cancer 69:863-867; 1994.
39. Mohrmann, M.; Pauli, A.; Schonfeld, B.; Walkenhorst, H; Brandis, M. Effects of ifosfamide metabolites on sodium dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Renal Physiol. Biochem. 16:285-298; 1993.
40. Mohrmann, M.; Ansorge, S.; Schmich, U.; Schonfeld, B.; Brandis, M. Toxicity of ifosfamide, cyclohosphamide and their metabolites in renal tubular cells in culture. Pediatr. Nephrol. 8:157-163; 1994.
41. Zamlauski-Tucker, M. J.; Morris, M. E.; Springate, J. E. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol. Appl. Pharmacol. 129:170-175; 1994.
42. Springate, J. E.; Zamlauski-Tucker, M. J.; Lu, H.; Chan, K. K. Renal clearance of ifosfamide. Drug Metab. Dispos. 25:1081-1082; 1997.
43. Harlan, J. M.; Levine, J. D.; Callahan, K. S.; Schwartz, B. R.; Harker, L. A. Glutathione redox cycle protects cultured endothelial cells against lysis by extracellular generated hydrogen peroxide. J. Clin. Invest. 73:706-713; 1984.
44. Halliwell, B.; Cross, C. E. Oxygen-derived species: Their relation to human disease and environmental stress. Environ. Health Perspect. 102:5-21; 1994.
45. Lind, M. J.; McGown, A. T.; Hadfield, J. A.; Thatcher, N.; Crowther, D.; Fox, B. W. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem. Pharmacol. 38:1835-1840; 1989.
46. Springate, J. E. Ifosfamide metabolite chloroacetaldehyde causes kidney dysfunction in vivo. J. Appl. Toxicol. 17:75-79; 1997.
47. Hamaguchi, T.; Azuma, J.; Awata, N.; Ohta, H.; Takihara, K.; Harada, H.; Kishimoto, S.; Sperelakis, N. Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. Res. Commun. Chem. Pathol. Pharmacol. 59:21-30; 1988.
48. Wang, Q.; Giri, S. N.; Hyde, D. M.; Li, C. Amelioration of bleomycin-induced pulmonary fibrosis in hamsters by combined treatment with taurine and niacin. Biochem. Pharmacol. 42:1115-1122; 1991.
49. Tadolini, B.; Pintus, G.; Pinna, G. G.; Bannardini, F.; Fanconi, F. Effects of taurine and hypotaurine on lipid peroxidation. Biochem. Biophys. Res. Commun. 213:820-826; 1995.
50. Venkatesan, N.; Rao, P. V.; Arumngam, V. In vivo protective effect of taurine on puromycin aminonucleoside-induced nephrosis in rats. J. Clin. Biochem. Nutr. 16:91-100; 1994.
51. Giri, S. N.; Blaisdell, R.; Rucker, R. B.; Wang, Q.; Hyde, D. M. Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation with taurine and niacin: Biochemical mechanisms. Environ. Health Perspect. 102:137-147; 1994.
52. Venkatesan, N.; Chandrakasan, G. In vivo administration of taurine and niacin modulate cyclophosphamide-induced lung injury. Eur. J. Pharmacol. 292:75-80; 1994.
53. Hamaguchi, T.; Azuma, J.; Harada, H.; Takahashi, K.; Kishimoto, S.; Schaffer, S. W. Protective effect of taurine against doxorubicin-induced cardiotoxicity in perfused chick hearts. Pharmacol. Res. 21:729-734; 1989.
54. Cerny, T.; Kupfer, A. The enigma of ifosfamide encephalopathy. Ann. Oncol. 3:679-681; 1992.